November 8, 2021

SZA Longevity has entered into a multi-year collaborative agreement with King’s College London to provide multi-omics services in support of drug development and related research efforts. SZA Longevity will leverage its proprietary platform to analyze a range of biological samples to accelerate research, drug development, and precision medicine.

SZA Longevity multi-omics projects is an essential element of the scientific approach that is being employed by King’s College London to transform healthcare by understanding disease progression and therapeutic response more deeply.

Through this collaboration, SZA Longevity will perform multi-omics analysis and provide a biological interpretation of results for large-scale population health initiatives, with the goal of accelerating King’s College London research and drug development initiatives.

SZA Longevity collaborates with King’s College London to enable novel discoveries and accelerate clinical Trials, quickly coordinate e-business applications through revolutionary catalysts for change. Seamlessly underwhelm optimal testing procedures processes. Capitalize on low hanging fruit to identify a ballpark value added activity to beta test.

November 8, 2021

We are pleased to inform that the Turkish Council for Scientific and Technological Research has granted us funding for our project, which is titled "Developing Healthy Life Practices Based on Current Omic Technologies."